SPHK1 regulates proliferation and survival responses in triplenegative breast cancer

Oncotarget

Volumn 5, Issue 15, 2014, Pages 5920-5933

  Datta, Arpita ^a   Loo, Ser Yue ^a,b   Huang, Baohua ^a   Wong, Lingkai ^c   Tan, Sheryl S L ^a   Tan, Tuan Zea ^b   Lee, Soo Chin ^b,d,e   Thiery, Jean Paul ^a,b,e,f   Lim, Yaw Chyn ^a   Yong, Wei Peng ^b,d,e   Lam, Yulin ^c   Kumar, Alan Prem ^a,b,e,g,h   Yap, Celestial T ^a,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e Singapore   (Singapore)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^g CURTIN UNIVERSITY   (Australia)

^h UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Breast cancer; Chemotherapy; Sphingosine kinase

Indexed keywords

2,2 DIMETHYL(1 OXO 2 HEXADECYN 1 YL) 1,1 DIMETHYLETHYL ESTER 3 OXAZOLIDINECARBOXYLIC ACID; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; SKI 5C; SMALL INTERFERING RNA; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG; PHOSPHOTRANSFERASE; SPHINGOSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME INHIBITION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HETEROGRAFTS; HUMANS; MCF-7 CELLS; MICE; MICE, SCID; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); TRANSFECTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84906274282     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1874     Document Type: Article

References (44)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-752.
2. Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A, Easton D and Lakhani SR. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007; 9(1):R4.
3. Brenton JD, Carey LA, Ahmed AA and Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005; 23(29):7350-7360.
4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21):2492-2502.
5. Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R and Clemons M. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009; 9(1):29-33.
6. Cleator S, Heller W and Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007; 8(3):235-244.
7. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW and Bang YJ. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 2007; 7:203.
8. Hardenbergh PH, Recht A, Gollamudi S, Come SE, Hayes DF, Shulman LN, O'Neill A, Gelman RS, Silver B and Harris JR. Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1999; 45(1):69-72.
9. Gamen S, Anel A, Perez-Galan P, Lasierra P, Johnson D, Pineiro A and Naval J. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res. 2000; 258(1):223-235.
10. Morse DL, Gray H, Payne CM and Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Molecular cancer therapeutics. 2005; 4(10):1495-1504.
11. Esteva FJ. The current status of docetaxel for metastatic breast cancer. Oncology. 2002; 16(6 Suppl 6):17-26.
12. Ogretmen B and Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004; 4(8):604-616.
13. Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R and Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem. 1998; 273(37):23722-23728.
14. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, Milstien S, Kohama T and Spiegel S. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem. 2000; 275(26):19513-19520.
15. Vadas M, Xia P, McCaughan G and Gamble J. The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim Biophys Acta. 2008; 1781(9):442-447.
16. Tan SS, Khin LW, Wong L, Yan B, Ong CW, Datta A, Salto-Tellez M, Lam Y and Yap CT. Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South asian population. Clinical and translational gastroenterology. 2014; 5:e51.
17. Hait NC, Oskeritzian CA, Paugh SW, Milstien S and Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta. 2006; 1758(12):2016-2026.
18. Spiegel S and Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem. 2002; 277(29):25851- 25854.
19. Spiegel S and Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003; 4(5):397-407.
20. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK and Smith CD. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003; 63(18):5962-5969.
21. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S, Geisslinger G, Holtrich U, Karn T and Kaufmann M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 2008; 112(1):41-52.
22. Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, Wiese TE, Burow ME and Beckman BS. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. Journal of molecular endocrinology. 2011; 46(3):205-216.
23. Sukocheva O, Wadham C and Xia P. Estrogen defines the dynamics and destination of transactivated EGF receptor in breast cancer cells: role of S1P(3) receptor and Cdc42. Exp Cell Res. 2013; 319(4):455-465.
24. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-10874.
25. Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY, Leong WY, Chan YS, Palanisamy N, Liu ET, Karuturi KM, Lim B, et al. RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest. 2009; 119(8):2171- 2183.
26. Hla T, Lee MJ, Ancellin N, Paik JH and Kluk MJ. Lysophospholipids--receptor revelations. Science. 2001; 294(5548):1875-1878.
27. Sukocheva O, Wang L, Verrier E, Vadas MA and Xia P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology. 2009; 150(10):4484-4492.
28. Nava VE, Hobson JP, Murthy S, Milstien S and Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res. 2002; 281(1):115-127.
29. Sukocheva OA, Wang L, Albanese N, Pitson SM, Vadas MA and Xia P. Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol Endocrinol. 2003; 17(10):2002-2012.
30. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, Collier C, Zhang M, Satin LS, Merrill AH, Jr., Milstien S and Spiegel S. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem. 2005; 280(44):37118-37129.
31. Takabe K, Kim RH, Allegood JC, Mitra P, Ramachandran S, Nagahashi M, Harikumar KB, Hait NC, Milstien S and Spiegel S. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem. 2010; 285(14):10477-10486.
32. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McGlynn LM, Pyne S, Pyne NJ and Edwards J. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signalregulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol. 2010; 177(5):2205-2215.
33. Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE, Wattenberg BW and Vadas MA. Phosphorylationdependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med. 2005; 201(1):49-54.
34. Fuereder T, Hoeflmayer D, Jaeger-Lansky A, Rasin-Streden D, Strommer S, Fisker N, Hansen BJ, Crevenna R and Wacheck V. Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Anticancer Drugs. 2011; 22(3):245- 252.
35. Song L, Xiong H, Li J, Liao W, Wang L, Wu J and Li M. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-kappaB pathway in human non-small cell lung cancer. Clin Cancer Res. 2011; 17(7):1839-1849.
36. Wong L, Tan SS, Lam Y and Melendez AJ. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J Med Chem. 2009; 52(12):3618-3626.
37. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006; 24(26):4236-4244.
38. Johnson WE, Li C and Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007; 8(1):118-127.
39. Billich A and Ettmayer P. Fluorescence-based assay of sphingosine kinases. Anal Biochem. 2004; 326(1):114-119.
40. Osborne CK, Hobbs K and Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985; 45(2):584-590.
41. Lazarus P, Dufour M, Isabel G and Panasci LC. In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-Dglucose versus melphalan utilizing the CFU-C and HTSCA assays. Cancer Chemother Pharmacol. 1986; 16(2):148- 152.
42. Tomayko MM and Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989; 24(3):148-154.
43. Mimnaugh EG, Fairchild CR, Fruehauf JP and Sinha BK. Biochemical and pharmacological characterization of MCF-7 drug-sensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice. Biochem Pharmacol. 1991; 42(2):391-402.
44. Gottardis MM, Robinson SP and Jordan VC. Estradiolstimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem. 1988; 30(1-6):311-314.